Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the cloudy skies looming over the Pharmalot campus. After all, the birds are still chirping and a cool breeze is wafting by. Moreover, this marks the middle of the week, which means we have managed to survive this far. And this calls for celebration, yes? So please join us as we hoist another cup of delicious stimulation. Remember, no prescription is required. Meanwhile, here are a few items of interest. Have a grand day and drop us a line if you hear something saucy. …

With its $74 billion acquisition of Celgene (CELG) set to be final later this year, Bristol-Myers Squibb (BMY) disclosed its new executive lineup, STAT notes. One notable absence from the roster: Chief Scientific Officer Dr. Tom Lynch, the pioneering oncologist who joined the company in March 2017. And one of the biggest changes will be that operations overseen by Lynch will be split into two different roles: One executive will run research and early development, while another will run late-stage development.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • File the last sentence under ‘The FDA really can’t win lately.’ And so JAMA pummels the FDA for not doing something when “Currently, regulations prohibit the FDA from disclosing the applications.”
    Sad that a federal agency would follow the regulations, isn’t it? (Pardon my irony …)

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy